

# Financial Tear Sheet

## Primary IR Contact

Ed Bell  
T +1 206-272-4345  
invest@ctibiopharma.com  
(mailto:invest@ctibiopharma.com)

## Transfer Agent

### Computershare

Mail:  
Computershare Investor Services  
P.O. Box 43078  
Providence, RI 02940-3078

Overnight Delivery:  
Computershare Investor Services  
250 Royall Street  
Canton, MA 02021  
United States of America

T: 312-588-4187  
F: 312-601-4332  
www.Computershare.com  
(http://www.computershare.com)

## Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

## Stock Performance: CTIC (Nasdaq)

Exchange NASDAQ CM (US Dollar)

Price **\$3.73**

Change  
(%) ▲ 0.03 (0.81%)

Volume 487,863

52 Week Low \$2.45

Market Cap \$234,904,866

Rolling EPS -1.03

PE Ratio 0

Shares Outstanding 62,977,176

Data as of 02/16/18 4:00 p.m. ET



## Recent Headlines & Events

Feb 14, 2018 - 4:07 p.m.

CTI BioPharma to Present at the 7th Annual  
Leerink Partners Global Healthcare  
Conference ([phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2332522](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2332522))

Feb 13, 2018 - 7:01 a.m.

CTI BioPharma Announces Closing Of  
Underwritten Public Offering Of Common  
Stock ([phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2332055](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2332055))

Feb 09, 2018 - 7:00 a.m.

CTI BioPharma Prices Underwritten Public  
Offering of \$60 Million of Common Stock  
([phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2331573](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2331573))

There are currently no events scheduled.

## Ownership Summary

### Shareholders

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	78	63.82	32.1	20,239,973
Mutual Fund	23	3.04	1.8	1,129,446
Insider *	7	2.77	1.1	691,405

*\*Insider values reflect direct beneficial ownership.*

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
BVF Partners L.P.	6,929,690	11.0	-1,666,667	02/09/18
OrbiMed Advisors, LLC	5,000,000	7.9	0	12/31/17
Stonepine Capital Management, LLC	2,150,000	3.4	315,162	01/11/18
NB Public Equity Komplementar ApS	1,356,635	2.2	90,000	12/31/16
The Vanguard Group, Inc.	850,881	1.4	-225,168	12/31/17
Sphera Funds Management Ltd.	833,633	1.3	0	12/31/17
Renaissance Technologies LLC	609,849	1.0	198,700	12/31/17
BlackRock Institutional Trust Company, N.A.	406,748	0.7	7,586	12/31/17
Kennedy Capital Management, Inc.	246,189	0.4	246,189	12/31/17
OxFORD Asset Management	183,301	0.3	132,090	12/31/17

*Data provided by Nasdaq. Minimum 15 minutes delayed.*